Related Experiment Video
Updated: May 13, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Research progress on circular RNA in the regulation of drug resistance in genitourinary cancers
Peng-Cheng Hu1, Jia-Tao Yao1, Ke-Jie Wang2
1Health Science Center, Ningbo University, Ningbo, 315101, Zhejiang, China.
Abstract:
In recent years, significant progress has been made in the management of genitourinary cancers, primarily due to advancements in surgical techniques, the emergence of targeted therapy and immunotherapy, and the refinement of chemotherapy agents. However, despite the expanding arsenal of treatment modalities, some patients still face challenges associated with drug resistance, which hinders efforts to improve survival rates. Circular RNAs (circRNAs) are covalently closed RNA molecules with a stable structure and a unique ability to form reverse splicing loops. Increasing evidence suggests that abnormal expression of circRNAs is significantly correlated with the occurrence of genitourinay cancers, indicating their potentials as diagnostic and prognostic biomarkers, as well as new targets for treatment. Although research on circRNAs in genitourinary cancers has progressed, it is still in the preliminary stage. This review summarizes the properties and functions of circRNAs, focusing on their molecular and cellular mechanisms involved in mediating cancer-related drug resistance in the genitourinary system, including autophagy, epithelial-mesenchymal transition, and glycolysis, etc. The clinical potential of circRNAs in regulating drug resistance is also carefully discussed.
Insights
Circular RNAs (circRNAs) show promise in overcoming drug resistance in genitourinary cancers. Understanding their role in mechanisms like autophagy and glycolysis could lead to new cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Genitourinary cancers have seen treatment advances, but drug resistance remains a significant challenge impacting survival rates.
- Circular RNAs (circRNAs), stable RNA molecules with unique structures, are increasingly implicated in various cancers.
- Abnormal circRNA expression correlates with genitourinary cancer occurrence, suggesting potential as biomarkers and therapeutic targets.
Purpose of the Study:
- To review the properties and functions of circRNAs.
- To explore the molecular and cellular mechanisms by which circRNAs mediate cancer-related drug resistance in genitourinary cancers.
- To discuss the clinical potential of circRNAs in overcoming drug resistance.
Main Methods:
- Literature review focusing on circRNAs in genitourinary cancers.
- Analysis of circRNA involvement in drug resistance mechanisms such as autophagy, epithelial-mesenchymal transition, and glycolysis.
- Discussion of current research status and future clinical applications.
Main Results:
- CircRNAs possess unique structural properties and diverse functions relevant to cancer biology.
- Abnormal circRNA expression is linked to the development and progression of genitourinary cancers.
- CircRNAs play critical roles in mediating drug resistance through pathways including autophagy, epithelial-mesenchymal transition, and glycolysis.
Conclusions:
- CircRNAs represent promising diagnostic and prognostic biomarkers for genitourinary cancers.
- Targeting circRNAs offers a novel therapeutic strategy to overcome drug resistance in genitourinary malignancies.
- Further research is needed to fully elucidate the clinical potential of circRNAs in managing genitourinary cancers.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:56Treatment Resistant Cancers
02:15Experimental RNAi
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...